PMSF

PMSF (Phenylmethanesulfonyl fluoride) is an irreversible inhibitor of serine proteinases, which is associated with the development of the delayed organophosphorus neuropathy. It has a role in a lot of cellular repair and regeneration processes in many kinds of tissues. PMSF is a long acting Neuropathy Target Esterase (NTE) inhibitor. NTE is a protection was related to inhibition of the putative target of organophosphate-induced delayed polyneuropathy (OPIDP) . PMSF can increase NTE inhibition to more than 90%. PMSF also acts as an active site directed reagent for γ-glutamyl transpeptidase. (In Vitro) :PMSF (2 mM) inhibits carbachol-stimulated inositol phosphate accumulation in the presence of Li+ by only 15%-19%. PMSF inhibition of phosphoinositide turnover is due to one or more steps following phosphoinositide breakdown. PMSF inhibits the acylation of the inositol residue of GPI intermediates in bloodstream form T. brucei. PMSF inhihits the formntion of glycolipid C but does not inhibit fatty acid remodeling in vitro. PMSF inhihits GPI acylation and ethanolamine phosphatp addition in procyclic trypanosomes but not in Hela cells. (In Vivo) :PMSF (0.1 mL/10 g b.wt, i.p.) produces antinociception as indicated by the dose-responsive increase in % MPE in the tail-flick latency evaluation, but fails to produce a clear dose-responsive inhibition of locomotion. Mice receiving i.p. injections of PMSF exhibit cannabinoid effects that includes antinociception, hypothermia and immobility with ED50 values of 86, 224 and 206 mg/kg, respectively. PMSF (30 mg/kg) pretreatment potentiates the effects of anandamide on tail-flick response (antinociception), spontaneous activity and mobility by 5-, 10- and 8-fold, respectively.